260 related articles for article (PubMed ID: 25417909)
21. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
[TBL] [Abstract][Full Text] [Related]
22. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.
Carrier P; Jaccard A; Jacques J; Tabouret T; Debette-Gratien M; Abraham J; Mesturoux L; Marquet P; Alain S; Sautereau D; Essig M; Loustaud-Ratti V
Liver Int; 2015 Oct; 35(10):2222-7. PubMed ID: 26104059
[TBL] [Abstract][Full Text] [Related]
23. [The Current Status and Research Progress of Antiviral Therapy in HCV-Associated Lymphoma --Review].
Sun XH; Wan S; Li ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1987-1990. PubMed ID: 34893147
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
25. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.
Hosry J; Mahale P; Turturro F; Miranda RN; Economides MP; Granwehr BP; Torres HA
Int J Cancer; 2016 Dec; 139(11):2519-28. PubMed ID: 27501007
[TBL] [Abstract][Full Text] [Related]
26. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.
La Mura V; De Renzo A; Perna F; D'Agostino D; Masarone M; Romano M; Bruno S; Torella R; Persico M
J Hepatol; 2008 Oct; 49(4):557-63. PubMed ID: 18678434
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus-associated indolent B-cell lymphomas: A review on the role of the new direct antiviral agents therapy.
Mazzaro C; Dal Maso L; Visentini M; Ermacora A; Andreone P; Gattei V; Pozzato G
Hematol Oncol; 2021 Oct; 39(4):439-447. PubMed ID: 34477233
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
[TBL] [Abstract][Full Text] [Related]
31. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.
Arcaini L; Bruno R
Curr Clin Pharmacol; 2010 May; 5(2):74-81. PubMed ID: 20156155
[TBL] [Abstract][Full Text] [Related]
33. Splenic large B-cell lymphoma in patients with hepatitis C virus infection.
Takeshita M; Sakai H; Okamura S; Oshiro Y; Higaki K; Nakashima O; Uike N; Yamamoto I; Kinjo M; Matsubara F
Hum Pathol; 2005 Aug; 36(8):878-85. PubMed ID: 16112004
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
[TBL] [Abstract][Full Text] [Related]
35. [Eight-year experience in treating aggressive mediastinal large B-cell lymphomas].
Mangasarova IaK; Magomedova AU; Kravchenko SK; Shmakov RG; Bariakh EA; Vorob'ev VI; Mar'in DS; Skidan NI; Gemdzhian ÉG; Misiurin AV; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2013; 85(7):50-6. PubMed ID: 24137947
[TBL] [Abstract][Full Text] [Related]
36. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
[TBL] [Abstract][Full Text] [Related]
37. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.
Arcaini L; Merli M; Volpetti S; Rattotti S; Gotti M; Zaja F
Clin Dev Immunol; 2012; 2012():638185. PubMed ID: 22956970
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas.
Silvestri F; Barillari G; Fanin R; Pipan C; Falasca E; Salmaso F; Zaja F; Infanti L; Patriarca F; Botta GA; Baccarani M
Haematologica; 1997; 82(3):314-7. PubMed ID: 9234578
[TBL] [Abstract][Full Text] [Related]
39. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
40. The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.
Kane E; Painter D; Smith A; Crouch S; Oliver S; Patmore R; Roman E
Cancer Epidemiol; 2019 Apr; 59():236-243. PubMed ID: 30844679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
